Cancer clinical trials in the region Pays de la Loire

445 currently recruiting clinical trials
Region Pays de la Loire

Phase 2 / Phase 3 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06943755 #2025-521043-20-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Exélixis
Phase 2 / Phase 3 Multiple myeloma #NCT07095452 #2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2 / Phase 3 Stomach and esophageal cancer #NCT07221149 #2025-523263-37-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1) CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
6 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3 Lung cancer #NCT07100080 #2025-521908-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
1 recruiting site
Bristol-Myers Squibb
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07106762 #2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3 Lung cancer #NCT05255302 #2024-515945-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR HER2 NTRK-1/2/3 RET ROS-1 Other mutation
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
13 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2 Penile cancer and germ cell tumors #NCT05529251 #2024-514636-25-00
Required histologic types
Germ cell tumor
Required histologic sub types
Pure seminoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required primary sites
Testis
Required IGCCCG prognostic scores
Good prognosis
Excluded previous treatments at localized stage
Surgery Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
12 recruiting sites
Centre Léon Bérard
Phase 2 Amyloidosis #NCT07549841 #2025-523616-36-00
Required histologic types
Other
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hôpital universitaire de Nantes
Phase 2 Lymphoma Brain tumors / Central nervous system tumors #NCT07015242 #2025-521144-38-00
Required histologic types
B cell lymphoma Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T Allogeneic stem cell transplant
9 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Lung cancer #NCT04919811 #2024-516604-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
10 recruiting sites
Thérapeutique AnHeart Inc